STOCK TITAN

Allarity Therapeutics Inc - ALLR STOCK NEWS

Welcome to our dedicated news page for Allarity Therapeutics (Ticker: ALLR), a resource for investors and traders seeking the latest updates and insights on Allarity Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Allarity Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Allarity Therapeutics's position in the market.

Rhea-AI Summary
Allarity Therapeutics publishes clinical validation of drug-specific companion diagnostic for dovitinib in renal cell carcinoma (RCC) patients, demonstrating improved clinical benefit compared to unselected patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.35%
Tags
none
-
Rhea-AI Summary
Allarity Therapeutics and FivepHusion have entered into a Clinical Collaboration Agreement to develop Deflexifol™ for the treatment of solid tumors. Allarity will use its drug-specific DRP® companion diagnostics to potentially select patients for clinical trials. Deflexifol™ is a reformulation of the chemotherapeutic agent 5-fluorouracil (5FU) and its biomodulator leucovorin (LV) to improve therapeutic activity. FivepHusion plans to start a phase 1b/2a study in H2 2023 to evaluate Deflexifol™ in combination with oxaliplatin and bevacizumab for unresectable metastatic colorectal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
-
Rhea-AI Summary
Allarity Therapeutics announces the appointment of three seasoned biotechnology executives to its Board of Directors. The new appointments are expected to bring expertise and strategic guidance to support the company's development efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
management
Rhea-AI Summary
Allarity Therapeutics announces pricing of public offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-53.99%
Tags
-
Rhea-AI Summary
Allarity Therapeutics announces promising results from Phase 2 clinical trial for IXEMPRA® in metastatic breast cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.43%
Tags
-
Rhea-AI Summary
Allarity Therapeutics, Inc. (NASDAQ: ALLR) announces a reverse stock split of its common stock at a ratio of 1 post-split share for every 40 pre-split shares. The split aims to increase the per share trading price and comply with Nasdaq's listing requirement. The reverse stock split will reduce the number of shares outstanding from 20,142,633 to approximately 503,565 shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.28%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.28%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.19%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.13%
Tags
none
Allarity Therapeutics Inc

Nasdaq:ALLR

ALLR Rankings

ALLR Stock Data

3.27M
308.66k
0.02%
0.94%
5.35%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Boston

About ALLR

oncology venture is a drug development company formed in 2012 dedicated to unlock the potential of new oncology products, and rescue failed drugs. our method improves the efficacy of the drugs, increase the response rate in cancer patients, reduce timelines and improve success rates in oncology drug development.